Analysis of Exploring Optimized Sequential Treatment Strategies of Antibody-Drug Conjugates (ADCs) in HER2-Low-Expressing Breast Cancer
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic…
Conditions studied
Antibody-drug Conjugates, HER2-low Breast Cancer, Breast Neoplasms
About this study
This study retrospectively analyzes the clinical data of HER2-low breast cancer (IHC 1+/2+ and FISH-negative) patients treated with sequential antibody-drug conjugates (ADCs). Key variables include patient demographics, tumor characteristics, ADC regimens (e.g., trastuzumab deruxtecan, sacituzumab govitecan), treatment sequencing, survival outcomes, and safety profiles. Genomic data (e.g., HER2 expression dynamics, TROP2 levels) are integrated to explore resistance mechanisms and prognostic biomarkers.mechanisms. This study aims to investigate the efficacy of different ADC sequential regimens in HER2-low breast cancer patients.
Interventions
- Other: Non-intervention research — Non-intervention research
Primary outcomes
- Progression-free survival (From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months.)
Eligibility information
Study locations
- Sun yat-sen University Cancer, Guangzhou, Guangdong 510060 China
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-29.